Incyte Corp. rose 2.7 percent after winning U.S. approval to sell the first treatment for patients with myelofibrosis, a rare bone-marrow disease.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
Click to continue reading this article or to log in to BostonGlobe.com.